Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FJUW5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,959
Award facts
- Contract value 100% obligated
- $27,959.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at approximately $28K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector units. The delivery order, issued on January 6, 2026, with an ultimate completion date of January 28, 2026, utilizes a firm fixed-price contract structure without set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical sourcing for Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has maintained a strong federal contracting presence since its SAM registration in 2001 and demonstrates substantial capacity to fulfill complex pharmaceutical supply requirements across therapeutic categories. The company's PPV-G GEN V contract, awarded in November 2025 with a ceiling value of $499,999,999 and a performance period extending through December 31, 2036, positions DMS Pharmaceutical Group as a critical regional prime vendor supplier. The company's established track record delivering specialized pharmaceuticals including immunosuppressants, biologics, and specialty medications to Department of Defense medical supply chains underscores its capability to support recurring military healthcare operations globally through the delivery order mechanism.
Quick answers
Who was awarded contract SPE2DR26FJUW5?
SPE2DR26FJUW5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FJUW5 worth?
The government has obligated $27,959 on SPE2DR26FJUW5.
Is contract SPE2DR26FJUW5 an order under another contract?
Yes. SPE2DR26FJUW5 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUW5 competed?
The extent of competition for SPE2DR26FJUW5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award